Oncology Drug Advisory Committee
Jump to navigation
Jump to search
This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (June 2019) |
The Oncologic Drugs Advisory Committee (ODAC) receives requests for technical and clinical evaluation of new drugs by the U.S. Food and Drug Administration (FDA). The committee, consisting of members from academic and clinical oncology biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat cancer.
References
- Oncologic Drugs Advisory Committee, official webpage: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/default.htm
External links
- FDA Advisory Committees Calendar (including ODAC): https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles lacking in-text citations from June 2019
- All articles lacking in-text citations
- Food and Drug Administration
- National agencies for drug regulation
- Regulators of biotechnology products
- Pharmacy organizations in the United States
- Cancer organizations based in the United States
- All stub articles
- Oncology stubs
- Pharmacology stubs